Donate

info@cureduchenne.org(949) 872-2552

COVID-19 Resources

Cart

×

No products in the cart.

Cure
Care
Community
About Us
CD Ventures
Get Involved
Donate

FibroGen Enrolls First Patients in Phase 2 Clinical Study of Anit-fibrotic Drug Candidate FG-3019 for the Treatment of Duchenne Muscular Dystrophy

January 6, 2016 - Posted in Research Articles

Related Posts

CureDuchenne Ventures Commits $500,000 to 4D Molecular Therapeutics to Advance Next-Generation AAV Delivery of Gene Therapy

September 7, 2018
Crispr Halted Muscular Dystrophy In Dogs. Someday, It Might Cure Humans.

August 30, 2018
Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated with Capricor’s Investigational Cell Therapy

November 15, 2017
Exonics Therapeutics Raises $40 Million in Series A Financing

November 8, 2017

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.

Donate

Search

Search for:

Recent Posts

NHL All-Star Ryan Getzlaf and CureDuchenne Raise $750,000 at 11th Annual Getzlaf Golf Shootout
September 22, 2022
Italfarmaco Webinar: Givinostat Development Program Updates
September 21, 2022
Duchenne Research Pipeline Explained
September 15, 2022
Adapt and Enjoy
September 14, 2022
The Millers and Ryan Getzlaf on NBC4
September 8, 2022

Categories

CureDuchenne Blog
Press Releases
In the News
Research Articles

Categories

All Categories
2022 FUTURES
Clinical Care
Community
Equipment
Financial Assistance
Industry Presentations
Mental Health
Physical Therapy
Recursos en español
Research and Clinical Trials
School

Connect With Us

Want to keep up to date with latest CureDuchenne news and announcements? Enter your email below to be added to our mailing list.

About
- Mission
- About Duchenne MD
- Team
- Blog
- Store
Get Involved
CureDuchenne
- 100 Bayview Circle, Suite 5600
  Newport Beach, CA 92660
  (949) 872-2552
  www.cureduchenne.org
Get Connected

PRIVACY POLICY | TERMS OF USE | INDIRECT COST POLICY | TAX INFO

CureDuchenne is a 501c3 registered tax-exempt nonprofit organization. Federal Tax ID: #20-0299958 | © CureDuchenne, 2024

Please be advised that the contents within the CureDuchenne site include a compilation of articles, advisements, and references from the community. CureDuchenne does not provide medical advice nor is CureDuchenne a medical provider. The intent of this shared content is to serve as a point of reference for informational purposes. Please refer to your health care provider(s) for your individualized, specific care management needs. The CureDuchenne website may contain links to external websites that are not provided and/or maintained by or in any way affiliated with CureDuchenne. CureDuchenne recommends that you review the terms of service and privacy policies of these external websites before entering. Please note that CureDuchenne does not guarantee the accuracy, relevance, timeliness, or completeness of any information on these external websites.